New targeted therapy shows promise for Hard-to-Treat kidney cancer
NCT ID NCT06649682
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-stage study tests a new drug called NYM096 for people with advanced clear cell kidney cancer that has spread. The drug is designed to find and treat cancer cells using a special imaging scan and targeted radiation. The study has two parts: first, using a low dose to see where the cancer is, and then giving higher doses to try to shrink tumors. About 20 adults who have already tried standard treatments will take part to check safety and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.